The trademark application OMPOVER was filed by AstraZeneca AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on June 3, 2015, and it was registered by office on September 10, 2015 without any oppositions.
The application was filed in English (French was selected as the second language).
The renewal of the trademark was recorded by the office on December 12, 2024.